SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGNX -- MacroGenics
MGNX 1.590-6.2%3:59 PM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (178)12/19/2019 2:34:24 PM
From: scaram(o)uche  Read Replies (1) of 188
 
Won't be long before tucatinib is approved. If I were a CD16A 158F-positive patient, I'd opt for tucatinib ALONE, first line. Then I'd go for marg next. Should only take a decade or so until tucatinib is first line.

:-(

Some have proposed that T is the dagger in M's heart. Wish that were true. Unfortunately, everyone makes it to salvage.

I don't understand, however, going for the 158F-negative patients. And Koenig has not effectively addressed that question.

Elegant work, validated in clinic.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News